Syntro Corporation

Schering-plough Animal Health Corporation

Schering-plough Veterinary Corporation

Prutech Research and Development Partnership

Intervet Inc.

The Texas A&m University System

Other

Schering Corporation

Prutech Research and Development

Intervet International B.v.

Schering-plough Corporation

Mark D Cochran

David E Junker

Richard D Macdonald

Martha A Wild

Barbara J Winslow

Christina H Chiang

William P MacConnell

Meng-Fu Shih

Ellen W Collisson

Lisa J Hock

Stephen V Lair

Richard M Synenki

Stephanie M Cook

Gary Petersen

Insoo Choi

Gregory P Pogue

Kenneth E Palmer

Mark L Smith

In-Soo Choi

InSoo Choi

Gary R Peterson

Phillip A Singer

Stephen Hash

Stephen M Hash

Steven V Lair

Richard Synenki

Martha Wild

Philip Singer

The present invention provides isolated and purified DNA encoding feline CD80 (B7-1) ligand, feline CD86 (B7-2) ligand, feline CD28 receptor, or feline CTLA-4 (CD152) receptor, as well as vectors comprising nucleic acid encoding feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a host cells transformed with CD80-encoding vectors, CD86-encoding vectors, CD28-encoding vectors, or CTLA-4-encoding vectors. The invention provides polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a vaccine comprising an effective amount of polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention also provides vaccines which further comprise immunogens derived from pathogens. The invention provides for vaccines capable of enhancing an immune response. The invention also provides for vaccines capable of suppressing and immune response.

Feline CD86 polypeptides and nucleic acids

The present invention discloses attenuatedorganisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin ofstrain 13, is missing at least nine consecutive amino acid residues including His. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.

Recombinant attenuated clostridium organisms and vaccine

The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to modulate the activity of GDF8, employing vaccines or antibodies according to the invention.

Neutralizing GDF8 epitope-based growth enhancing vaccine

The present invention provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene. This attenuated virus is useful as a vaccine against infectious laryngotracheitis virus. The present invention also provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the US2 gene, UL47-like gene, ORF4 gene or glycoprotein g60 gene. The present invention also provides a method for distinguishing chickens or other poultry vaccinated with a recombinant infectious laryngotracheitis virus which produces no glycoprotein gG from those infected with a naturally-occurring infectious laryngotracheitis virus.

Recombinant infectious laryngotracheitis virus and uses thereof

[object Object]

Feline CTLA-4 nucleic acid and polypeptides

The invention provides new, specific nucleic acids encoding antigenic peptides from the protein GDF8. The invention also provides nucleic acids encoding fusion proteins comprising the new peptides, immunogens and vaccines based on the nucleic acids encoding new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to modulate the activity of GDF8, employing vaccines or antibodies according to the invention.

Nucleic acids encoding neutralizing GDF8 epitope-based peptides and fusion proteins

The invention provides a fusion protein comprising a plant virus coat protein and a GDF8 peptide domain, or antigenic fragment of the GDF8 peptide domain. Plant virus vectors expressing the fusion protein and methods of using these vectors are also provided.

Plant virus coat fusion proteins with GDF8 epitopes and vaccines thereof

The present invention provides recombinant and/or isolated infectious laryngotracheitis virus glycoproteins, including gD, gI, gG and gE.

The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.

Recombinant avian herpesvirus useful in vaccine production

The present invention involves a recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome of a virus, wherein each such foreign nucleic acid encodes a protein. The protein which is encoded is selected from the groups consisting of a feline CD28 protein or an immunogenic portion thereof, a feline cD80 protein or an immunogenic portion thereof, a feline CD86 protein or an immunogenic portion thereof, or a feline CTLA-4 protein or an immunogenic portion thereof. The protein is capable of being expressed when the recombinant virus is introduced into an appropiate host. The present invention also involves a recombinant virus further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen. The present invention also comprises recombinant viruses which are capable of enhancing an immune response in a feline. The present invention also comprises recombinant viruses which are capable of suppressing an immune respons in a feline.

Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof

The present invention provides isolated and purified DNA encoding feline CD80 (B7-1) ligand, feline CD86 (B7-2) ligand, feline CD28 receptor, or feline CTLA-4 (CD152) receptor, as well as vectors comprising nucleic acid encoding feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a host cells transformed with CD80-encoding vectors, CD86-encoding vectors, CD28-encoding vectors, or CTLA-4-encoding vectors. The invention provides polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4.

Nucleic acid encoding feline CD86

Growing community of inventors

Carlsbad, CA, United States of America

Mark D Cochran